Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Total Debt (2024 - 2025)

Karyopharm Therapeutics' Total Debt history spans 2 years, with the latest figure at $115.8 million for Q4 2025.

  • For Q4 2025, Total Debt rose 22.41% year-over-year to $115.8 million; the TTM value through Dec 2025 reached $115.8 million, up 22.41%, while the annual FY2025 figure was $115.8 million, 22.41% up from the prior year.
  • Total Debt reached $115.8 million in Q4 2025 per KPTI's latest filing, up from $96.4 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $115.8 million in Q4 2025 to a low of $93.5 million in Q2 2024.